Clinical Trials Sponsored by Armgo Pharma, Inc.

Total 2366 results

Astellas Pharma Global Development, Inc.

Completed

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

Renal Impairment | Healthy Volunteers

United States, Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

Renal Impairment | Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause (Skylight 4)

Hot Flashes

United States, Czechia, Canada, Latvia, Poland, Spain, Ukraine, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 (Skylight 2)

Hot Flashes

United States, Canada, Czechia, United Kingdom, Latvia, Poland, Spain
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

Cytomegalovirus (CMV)-Positive Recipients | Allogeneic, Hematopoietic Cell Transplant (HCT)

Japan, Korea, Republic of, United States, Canada, Australia, Belgium, France, Germany, Spain, Sweden, Taiwan
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States
Astellas Pharma Global Development, Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Schizophrenia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

Fibromyalgia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Healthy Subjects

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Relapsed Lymphoid Malignancy | Refractory Lymphoid Malignancy

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) (PREFER)

Overactive Bladder (OAB)

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
Astellas Pharma Global Development, Inc.

Completed

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer (PILOT)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Germany, Latvia
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Assess ASP2713 in Healthy Subjects

Healthy Volunteers
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis (RA)

United States, Poland
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Lymphoma | Advanced Cancer | Refractory Solid Tumors

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Moldova, Republic of
Astellas Pharma Global Development, Inc.

Completed

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Advanced Solid Tumors | Pharmacokinetics of 14C-OSI-906

United States
Astellas Pharma Inc
Astellas Pharma Global Development, Inc.

Completed

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Solid Tumors

United States, Japan, Korea, Republic of, Taiwan
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Astellas Pharma Global Development, Inc.

Completed

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Healthy Volunteers | Pharmacokinetics of ASP1941

United States
Traws Pharma, Inc.

Recruiting

Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers

Healthy Volunteers Only

Australia
Nuvectis Pharma, Inc.

Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Advanced Solid Tumor

United States, United Kingdom
Aneira Pharma, Inc.

Recruiting

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

Hypotrichosis

United States
Vincerx Pharma, Inc.

Recruiting

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Neoplasms

Australia, United States
Klus Pharma Inc.

Recruiting

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Solid Tumor

China
Kringle Pharma, Inc.

Recruiting

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Acute Spinal Cord Injury

Japan
Klus Pharma Inc.

Recruiting

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)

Breast Cancer | Non-Small Cell Lung Cancer | Gastric Adenocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Small-Cell Lung Cancer

United States, China
OBI Pharma, Inc

Recruiting

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Triple Negative Breast Cancer

China, Taiwan, United States, Korea, Republic of, Australia, Brazil, Hong Kong, Mexico, Russian Federation, South Africa, Ukraine, Peru, Poland
MEI Pharma, Inc.

Recruiting

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United States
Astellas Pharma Inc

Completed

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastro-esophageal Junction (GEJ) Cancer

Japan
Astellas Pharma Inc

Terminated

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy (MOUNTAINSIDE)

Primary Mitochondrial Myopathy

United States
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
MEI Pharma, Inc.

Active, not recruiting

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Colorectal Cancer

United States
OBI Pharma, Inc

Terminated

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Taiwan
aTyr Pharma, Inc.

Completed

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)

Limb-Girdle Muscular Dystrophies | Facioscapulohumeral Muscular Dystrophy

United States, Denmark, France
aTyr Pharma, Inc.

Completed

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, France, Italy
Astellas Pharma Inc

Terminated

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Ocular Hypertension | Open Angle Glaucoma

United States
Acasti Pharma Inc.

Completed

Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

Aneurysmal Subarachnoid Hemorrhage

Canada
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Mydriasis | Dilation

United States

3

Subscribe